Published in AIDS Weekly, June 24th, 2002
Jeanne C. Keruly and colleagues at Johns Hopkins University School of Medicine in Baltimore and the Health Resources and Services Administration in Rockville, Maryland conducted a study to "assess sociodemographic and medical insurer factors associated with receipt of highly active antiretroviral therapy (HAART)."
Although socioeconomic factors still influence treatment options, the benefits of HAART are becoming more accesible to poor and minority patients, Keruly and coauthors...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2002-06-24)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.